On Friday, Mersana Therapeutics Inc (NASDAQ: MRSN) opened lower -2.89% from the last session, before settling in for the closing price of $0.36. Price fluctuations for MRSN have ranged from $0.26 to $2.83 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 2.74% over the past five years. Company’s average yearly earnings per share was noted -6.99% at the time writing. With a float of $96.84 million, this company’s outstanding shares have now reached $124.63 million.
Let’s look at the performance matrix of the company that is accounted for 102 employees. In terms of profitability, gross margin is 100.0%, operating margin of -225.98%, and the pretax margin is -216.41%.
Mersana Therapeutics Inc (MRSN) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Mersana Therapeutics Inc is 22.30%, while institutional ownership is 50.01%. The most recent insider transaction that took place on Jan 16 ’25, was worth 2,061. In this transaction VP, Chief Accounting Officer of this company sold 3,554 shares at a rate of $0.58, taking the stock ownership to the 57,519 shares. Before that another transaction happened on Jan 16 ’25, when Company’s Director sold 8,637 for $0.58, making the entire transaction worth $5,009. This insider now owns 168,041 shares in total.
Mersana Therapeutics Inc (MRSN) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -6.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.65% during the next five years compared to 2.74% growth over the previous five years of trading.
Mersana Therapeutics Inc (NASDAQ: MRSN) Trading Performance Indicators
Check out the current performance indicators for Mersana Therapeutics Inc (MRSN). In the past quarter, the stock posted a quick ratio of 1.83. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.60, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.58 in one year’s time.
Technical Analysis of Mersana Therapeutics Inc (MRSN)
Mersana Therapeutics Inc (NASDAQ: MRSN) saw its 5-day average volume 1.62 million, a negative change from its year-to-date volume of 4.15 million. As of the previous 9 days, the stock’s Stochastic %D was 60.65%.
During the past 100 days, Mersana Therapeutics Inc’s (MRSN) raw stochastic average was set at 30.18%, which indicates a significant decrease from 69.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0290 in the past 14 days, which was lower than the 0.0399 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3487, while its 200-day Moving Average is $0.9870. Nevertheless, the first resistance level for the watch stands at $0.3692 in the near term. At $0.3855, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.3978. If the price goes on to break the first support level at $0.3406, it is likely to go to the next support level at $0.3283. The third support level lies at $0.3120 if the price breaches the second support level.
Mersana Therapeutics Inc (NASDAQ: MRSN) Key Stats
There are currently 124,631K shares outstanding in the company with a market cap of 43.97 million. Presently, the company’s annual sales total 40,500 K according to its annual income of -69,190 K. Last quarter, the company’s sales amounted to 2,750 K and its income totaled -24,120 K.
